Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528209) titled 'Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer' on April 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-sen University
Condition:
Rectal Cancer
pMMR (Microsatellite Stable Rectal Cancer)
Intervention:
Drug: Pucotenlimab combine with CAPOX
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: April 20, 2026
Target Sample Size: 556
Countries of Recruitment:
China
To know more, visit...